)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Damora Therapeutics
Damora Therapeutics (DMRA) investor relations material
Damora Therapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary10 Aug, 2026
Strategic vision and leadership
Focused on redefining care for blood disorders, particularly myeloproliferative neoplasms (MPNs) driven by CALR mutations.
Founded by Fairmount Funds Management, with experienced R&D and commercial leadership.
Supported by premier investors and listed on NASDAQ.
Pipeline and clinical development
Lead asset DMR-001 is a next-generation anti-mutCALR antibody with superior potency and exposure, targeting both Type 1 and Type 2 mutations.
DMR-001 is designed for convenient, infrequent subcutaneous dosing via autoinjector, aiming for best-in-class efficacy and patient experience.
Additional assets DMR-002 (Fc-enhanced) and DMR-003 (T-cell engager) are advancing toward regulatory submissions in 2026 and 2027.
Phase 1/1b CLARITY-101 trial for DMR-001 initiated in Q3 2026, with two clinical proof-of-concept readouts expected beginning mid-2027.
Market opportunity and competitive positioning
Estimated US addressable market for mutCALR-driven MPNs exceeds $5B, with ~42,000 patients eligible for targeted therapy.
DMR-001 is positioned to capture significant market share due to its convenient SC dosing and potential for first-to-market status.
Current standard of care leaves significant unmet need, with many patients resistant or intolerant to existing therapies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Damora Therapeutics
- Net loss rose to $31.2M in Q2 2026 as R&D surged; cash reserves hit $540.5M.DMRA
Q2 2026 - All proposals passed, including director elections and auditor ratification, with strong shareholder support.DMRAAGM 2026
- Next-gen antibody therapies for CALR-driven MPNs, with strong financials and clinical momentum.DMRACorporate presentation
- Q1 2026 net loss was $27.8M; $532.9M cash funds pipeline into 2029, more capital needed later.DMRAQ1 2026
- Virtual meeting to vote on directors, executive pay, and auditor ratification June 17, 2026.DMRAProxy filing
- Annual meeting to vote on directors, executive pay, auditor, and ESG oversight.DMRAProxy filing
- Cash position of $535M supports pipeline progress; net loss driven by R&D acquisition costs.DMRAQ4 2025
- Damora advances potent CALR-targeted therapies for ET and MF, aiming for broad clinical impact.DMRALeerink Global Healthcare Conference 2026
- Key proposals include stock conversion, capital increase, redomestication, and new equity plans.DMRAProxy Filing
Next Damora Therapeutics earnings date
Q3 20264 Nov, 2026
Damora Therapeutics
Next Damora Therapeutics earnings date
Q3 20264 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Galecto Inc. is a clinical-stage biotechnology company primarily focused on the development of small molecule therapeutics aimed at critical aspects of cancer and fibrotic diseases. Their research and development efforts are centered around the inhibition of galectin-3 and lysyl oxidase-like 2 (LOXL2), proteins that play a pivotal role in the progression of these conditions. Galecto's portfolio includes GB0139, designed for treating Idiopathic Pulmonary Fibrosis (IPF), a serious progressive fibrotic lung disease; GB1211, a selective oral small molecule inhibitor of galectin-3 for various oncology indications and liver cirrhosis; and GB2064, targeting LOXL2 for the treatment of myelofibrosis. The company is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.